Top 20 Prescription Drugs of 2025 

Shots: 

• In 2025, the global Prescription Drugs market is projected to generate an impressive $1.13T, with steady annual growth of 3.94% expected through 2030, ultimately reaching $1.37T. Leading the pack is Keytruda, securing the first position with $29.48B, closely followed by Ozempic at $28.18B, and Eliquis, which recorded $20.69B in global sales. Fourth position is held by Mounjaro which has gained 208% growth in last one year 

• The pharmaceutical market is experiencing a historic shift toward metabolic diseases, with GLP-1 agonists and tirzepatide therapies exploding in growth to capture nearly $45B in combined revenue, while oncology and immunology treatments like Keytruda and Skyrizi maintain robust expansion 

• Meanwhile, legacy blockbusters face significant pressure from biosimilar competition and normalized demand, with Humira collapsing 38% and Comirnaty dropping 49%, reflecting a market transition away from older treatments toward specialized, next-generation therapies. 

Rank	Drug	2023 Total  Revenue ($B)	2024 Total  Revenue ($B)	Percent  Change (%)
1	Keytruda	25.01	29.48	17.87
2	Ozempic/Wegovy/Rybelsus	21.58	28.18	30.58
3	Eliquis	18.95	20.69	9.18
4	Mounjaro/Zepbound	5.33	16.46	208.81
5	Dupixent	11.58	14.14	22.1
6	Biktarvy	11.85	13.42	13.24
7	JARDIANCE family	10.89	12.04	10.56
8	Skyrizi	7.76	11.71	50.9
9	Darzalex	9.74	11.67	19.81
10	Stelara	10.85	10.36	-4.51
11	Trikafta/Kaftrio	8.94	10.23	14.42
12	Eylea/Eylea HD	9.38	9.54	1.7
13	Opdivo	9	9.3	3.33
14	Humira	14.4	8.99	-37.56
15	Gardasil/Gardasil 9	8.88	8.58	-3.37
16	Comirnaty	15.38	7.88	-48.76
17	Entresto	6.03	7.82	29.68
18	Farxiga/Forxiga	5.96	7.65	28.35
19	Ocrevus	7.58	7.46	-1.58
20	Tagrisso	5.79	6.58	13.64

20. Tagrisso 

Proprietary Name: Tagrisso 

Non-Proprietary Name: Osimertinib 

Company: AstraZeneca 

First Approved: US (Nov 13, 2015), EU (Feb 1, 2016)  

Total Revenue: $6.58B  

Indications Approved: EGFR mutation-positive non-small cell lung cancer (NSCLC), including T790M mutation, first-line metastatic EGFR exon 19 deletion/exon 21 L858R, adjuvant therapy after tumor resection, combination with chemotherapy in first-line metastatic setting 

• Tagrisso is a third-generation EGFR tyrosine kinase inhibitor (TKI) specifically engineered to target both sensitizing EGFR mutations and the T790M resistance mutation, while minimizing impact on wild-type EGFR 

• By irreversibly binding to mutant EGFR (including T790M), Tagrisso shuts down key cancer-driving signalling pathways, triggering tumor cell apoptosis and promoting tumor regression in patients with EGFR-mutated NSCLC. In FY 2024, Tagrisso delivered strong performance with a 13.64% revenue increase, fueled by robust global demand across adjuvant and first-line treatment settings 

• Further strengthening its clinical reach, the US FDA granted approval in Sep’24 for Tagrisso in patients with unresectable, Stage III EGFR-mutated lung cancer, expanding its role across earlier stages of disease management 

19. Ocrevus 

Proprietary Name: Ocrevus 

Non-Proprietary Name: Ocrelizumab 

Company: Roche 

First Approved: US (Mar 28, 2017), EU (Jan 08, 2018) 

Total Revenue: $7.46B 

Indications Approved: Multiple Sclerosis 

• Ocrevus is a humanized monoclonal antibody designed to treat both relapsing and primary progressive forms of multiple sclerosis (MS) 

• The therapy works through antibody-dependent cellular cytolysis and complement-mediated lysis, effectively depleting harmful B cells. In 2024, Ocrevus generated slightly lower revenue, declining 1.58% year over year. While the treatment continued to see growth in CHF, overall sales dipped in USD primarily due to currency fluctuations 

• Adding to its clinical momentum, the US FDA approved Ocrevus Zunovo, a twice-yearly, 10-minute injection option in Sep’24, offering patients a faster and more convenient administration method for managing multiple sclerosis 

18. Farxiga/Forxiga 

Proprietary Name: Farxiga/Forxiga 

Non-Proprietary Name: Dapagliflozin 

Company: AstraZeneca 

First Approved: US (Jan 8, 2014), EU (Nov 11, 2012) 

Total Revenue: $7.65B 

Indications Approved: Type 2 Diabetes, Heart Failure, Chronic Kidney Disease 

• Marketed as Farxiga in the US and Forxiga in the EU, dapagliflozin is a once-daily oral therapy approved for type 2 diabetes, heart failure, and chronic kidney disease 

• Farxiga works by selectively and reversibly inhibiting the SGLT-2 transporter in the kidney’s proximal tubule. This reduces glucose reabsorption and promotes urinary glucose excretion, ultimately helping patients achieve better glycemic control while also offering proven cardiovascular and renal benefits. In 2024, Farxiga/Forxiga sales jumped by 28.35% compared to 2023, fueled by strong demand in heart failure and CKD, as healthcare providers increasingly adopt SGLT-2 inhibitors as foundational therapy across multiple conditions 

• Adding to its momentum, in Jun’24, the US FDA approved Farxiga for pediatric type 2 diabetes, expanding its use to younger patients who face limited treatment options 

17. Entresto 

Proprietary Name: Entresto 

Non-Proprietary Name: Sacubitril/Valsartan 

Company: Novartis 

First Approved: US (Jul 7, 2015), EU (Nov 19, 2015) 

Total Revenue: $7.82B 

Indications Approved: Adult Heart Failure, Pediatric Heart Failure 

• Entresto, a combination of sacubitril and valsartan, is an angiotensin receptor–neprilysin inhibitor (ARNi) approved for treating both adult and pediatric heart failure. It has become a key therapy in improving outcomes for patients with chronic heart failure 

• The drug works through a dual mechanism: LBQ657, the active metabolite of sacubitril, blocks neprilysin (NEP), while valsartan inhibits the angiotensin II type-1 (AT1) receptor. Together, these actions help reduce strain on the heart, improve blood flow, and support better long-term cardiac function. In 2024, Entresto delivered strong growth, with revenue increasing 29.68% compared with 2023, driven largely by expanded adoption in Europe and the United States 

• In Mar’24, Novartis received approval in Japan for Entresto Granular Tablets for Pediatric Use, offering a new formulation designed specifically for children with chronic heart failure (CHF) 

16. Comirnaty  

Proprietary Name: Comirnaty  

Non-Proprietary Name:  

Company: Pfizer, BioNTech  

First Approved: US (Aug 23, 2021), EU (Oct 10, 2022)  

Total Revenue: $7.88B  

Indications Approved: COVID-19  

• Comirnaty is a COVID-19 vaccine approved for active immunization against SARS-CoV-2 in individuals aged 12 and older 

• The vaccine uses lipid-encapsulated mRNA that encodes the SARS-CoV-2 spike (S) antigen, prompting the body to generate neutralizing antibodies and activate cellular immune defenses. In 2024, Comirnaty’s sales declined 48.76% compared with 2023, reflecting a global drop in COVID-19 vaccine demand 

• In Oct’24, the UK’s MHRA approved a Comirnaty formulation targeting the KP.2 COVID-19 subvariant for use in adults, marking an important update aimed at keeping vaccination aligned with evolving viral strains 

15. Gardasil & Gardasil-9  

Proprietary Name: Gardasil & Gardasil-9  

Non-Proprietary Name: Human Papillomavirus  

Company: Merck & Co.  

First Approved: US (Gardasil-Jun 06, 2006; Gardasil-9- Dec 10, 2014), EU (Gardasil-Sep 20, 2006; Gardasil-9- Jun 10, 2015)  

Total Revenue: $8.58B  

Indications Approved: Gardasil – HPV (types 6, 11, 16, and 18) Gardasil-9 – HPV (types 6, 11, 16, 18, 31, 33, 45, 52, and 58) 

• Gardasil (quadrivalent) is approved for protection against HPV types 6, 11, 16, and 18 in individuals aged 9-26, while Gardasil 9 (the 9-valent vaccine) expands coverage to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 for individuals aged 9-45 

• Both vaccines stimulate strong humoral immune responses, helping prevent HPV-related cancers and diseases. In 2024, overall revenue declined 3.37% compared with 2023, largely due to reduced sales in China 

• Looking ahead, Merck announced plans in 2024 to initiate a clinical study evaluating a next-generation investigational multivalent HPV vaccine, as well as exploring a potential single-dose regimen for Gardasil 9, signaling continued innovation in HPV prevention 

14. Humira 

Proprietary Name: Humira 

Non-Proprietary Name: Adalimumab 

Company: AbbVie 

First Approved: US (Dec 31, 2002), EU (Sep 8, 2003) 

Total Revenue: $8.99B 

Indications Approved: Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Ulcerative Colitis, Plaque Psoriasis, Hidradenitis Suppurativa, Uveitis 

• Humira is a subcutaneous injectable therapy used to treat a wide range of autoimmune and inflammatory conditions 

• As a tumor necrosis factor (TNF) inhibitor, Humira works by blocking TNF-α, a key driver of inflammation, helping reduce symptoms and prevent disease progression. However, in 2024, Humira’s revenue declined 37.56% compared with 2023, primarily due to mounting biosimilar competition following its loss of exclusivity on January 31, 2023 

• With multiple biosimilars gaining regulatory approval and rapidly entering global markets, competition continues to intensify, reshaping the landscape for TNF inhibitors and accelerating the shift toward lower-cost alternatives 

13. Opdivo 

Proprietary Name: Opdivo 

Non-Proprietary Name: Nivolumab 

Company: Bristol-Myers Squibb & Ono Pharmaceuticals 

First Approved: US (Dec 22, 2014), EU (Jun 19, 2015) 

Total Revenue: $9.3B 

Indications Approved: Melanoma, Non-Small Cell Lung Cancer, Malignant Pleural Mesothelioma, Renal Cell Carcinoma, Classical Hodgkin Lymphoma, Squamous Cell Carcinoma of the Head and Neck, Urothelial Carcinoma, Colorectal Cancer, Hepatocellular Carcinoma, Esophageal Cancer, Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma 

• Opdivo is a human IgG4 monoclonal antibody approved for a broad range of cancers 

• By binding to the PD-1 receptor, Opdivo blocks its interaction with PD-L1 and PD-L2, effectively releasing the brakes on the immune system and enabling T-cells to attack tumor cells more effectively. In 2024, its global sales increased 3.33% compared with 2023, reflecting steady, though modest, growth in worldwide demand 

• A notable advancement came in Dec’24, when the US FDA approved Opdivo Qvantig Injection for subcutaneous use across most previously approved adult solid tumor indications, expanding patient access and offering a more convenient alternative to IV administration 

12. Eylea/Eylea HD 

Proprietary Name: Eylea/Eylea HD 

Non-Proprietary Name: Aflibercept 

Company: Regeneron Pharmaceuticals, Bayer 

First Approved: Eylea [US (Nov 18, 2011), EU (Nov 21, 2012)], Eylea HD [US (Aug 18, 2023)] 

Total Revenue: $9.54B 

Indications Approved: Neovascular (Wet) Age-Related Macular Degeneration, Diabetic Macular Oedema, Retinopathy of Prematurity, Diabetic Retinopathy 

• Eylea is a vascular endothelial growth factor (VEGF) inhibitor delivered via intravitreal injection for the treatment of several major retinal diseases, including neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), diabetic retinopathy, and retinopathy of prematurity 

• Functioning as a soluble decoy receptor, Eylea binds to VEGF-A and PlGF, preventing them from activating VEGF receptors and halting the abnormal blood vessel growth that can lead to vision loss. In 2024, global sales increased 1.7% compared with 2023, reflecting consistent and steady demand across global markets 

• A key milestone came in Jan’24, when Japan’s MHLW approved Eylea 8 mg (aflibercept 8 mg) for nAMD and DME, supported by strong data from the PULSAR and PHOTON studies, further enhancing treatment options for patients with retinal disease 

11. Trikafta/Kaftrio 

Proprietary Name: Combination of Trikafta/Kaftrio 

Non-Proprietary Name: Elexacaftor/tezacaftor/ivacaftor 

Company: Vertex 

First Approved: US (Oct 21, 2019), EU (Aug 21, 2020) 

Total Revenue: $10.23B 

Indications Approved: Cystic Fibrosis 

• Marketed as Trikafta in the US and Kaftrio in the EU, this triple-combination therapy: ivacaftor, tezacaftor, and elexacaftor, is a cornerstone treatment for cystic fibrosis (CF) 

• By improving chloride and sodium ion transport, Trikafta/Kaftrio helps address the underlying fluid imbalance that drives many CF symptoms. Its effectiveness is closely tied to the patient’s specific CF gene mutations, making it a highly targeted precision therapy. In 2024, global sales climbed 14.42% over 2023, fueled by sustained demand, expanded indications, treatment of younger age groups, and improved net pricing in the US 

• A major milestone arrived in Dec’24, when the US FDA expanded Trikafta’s approval to include children aged 2 years and older with at least one F508del mutation or another Trikafta-responsive mutation, significantly broadening access to this transformative therapy 

10. Stelara 

Proprietary Name: Stelara 

Non-Proprietary Name: Ustekinumab 

Company: Johnson & Johnson 

First Approved: US (Sep 25, 2009), EU (Jan 15, 2009) 

Total Revenue: $10.36B 

Indications Approved: Plaque Psoriasis (Ps), Crohn’s Disease, Psoriatic Arthritis (PsA), Ulcerative Colitis 

• Stelara remains a powerhouse therapy, delivering strong impact across a broad spectrum of immune-mediated and autoimmune disorders 

• As an interleukin inhibitor, Stelara targets and blocks IL-12 and IL-23, two cytokines that drive inflammation, swelling, and associated skin and gastrointestinal symptoms. Despite its broad utility, Stelara’s total sales in 2024 declined 4.51% from 2023, largely due to intensifying biosimilar competition 

• A notable development arrived in May’24, when Johnson & Johnson reported that Tremfya demonstrated superiority over Stelara in a Phase III study for Crohn’s disease, signalling a significant shift within the J&J’s own immunology portfolio 

9. Darzalex 

Proprietary Name: Darzalex 

Non-Proprietary Name: Daratumumab 

Company: Johnson & Johnson 

First Approved: US (Nov 16, 2015), EU (May 20, 2016) 

Total Revenue: $11.67B 

Indications Approved: Multiple Myeloma 

• Darzalex (daratumumab) is a human anti-CD38 monoclonal antibody approved for the treatment of multiple myeloma 

• By binding to CD38 on the surface of myeloma cells, daratumumab triggers cell death through multiple mechanisms, including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and inhibition of mitochondrial transfer. In 2024, Darzalex continued its strong commercial momentum, with revenue increasing 19.81% over 2023, driven by rising global demand 

• 2024 also brought an important regulatory milestone: the US FDA approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) for use in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation therapy in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplant (ASCT); further expanding its role across the treatment continuum 

8. Skyrizi 

Proprietary Name: Skyrizi 

Non-Proprietary Name: Risankizumab 

Company: AbbVie 

First Approved: US (Apr 23, 2019), EU (Apr 26, 2019) 

Total Revenue: $11.71B 

Indications Approved: Plaque Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis 

• Skyrizi is a humanized monoclonal antibody available as both a subcutaneous (SC) and intravenous (IV) injection, approved to treat multiple autoimmune disorders 

• As an IgG1 monoclonal antibody targeting interleukin-23 (IL-23), Skyrizi binds specifically to the p19 subunit of IL-23, blocking its interaction with the IL-23 receptor, thereby interrupting a key inflammatory pathway involved in multiple immune-mediated diseases. In 2024, Skyrizi continued its exceptional growth trajectory, with revenue rising 50.9% over 2023, fueled by strong and expanding global demand 

• A significant milestone came in Jun’24, when the US FDA approved Skyrizi (risankizumab-rzaa) for the treatment of ulcerative colitis, further solidifying its position as a leading therapy across inflammatory and autoimmune conditions 

7. JARDIANCE Family 

Proprietary Name:  

Non-Proprietary Name: Empagliflozin  

Company: Novartis and Boehringer Ingelheim (BI) 

First Approved: US (Feb 07, 2018), EU (Jun 21, 2018) 

Total Revenue: $12.04B 

Indications Approved:  

• The Jardiance family includes four key products, Jardiance, Synjardy, Synjardy XR, Glyxambi, and Trijardy XR; all built around the same active ingredient empagliflozin 

• Empagliflozin works by inhibiting the sodium–glucose co-transporter-2 (SGLT2) in the kidneys, reducing glucose reabsorption and increasing its excretion through urine. This mechanism not only supports better glycemic control but also delivers meaningful cardiovascular and renal benefits. In 2024, the Jardiance portfolio continued its upward trajectory, posting a 10.56% increase in revenue, fueled by strong global adoption  

• 2024 also brought a major regulatory win: India’s CDSCO approved Jardiance for the treatment of adults with chronic kidney disease (CKD), further expanding its therapeutic impact. 

6. Biktarvy 

Proprietary Name: Biktarvy 

Non-Proprietary Name: Combination of Bictegravir, Emtricitabine, and Tenofovir Alafenamide 

Company: Gilead Sciences 

First Approved: US (Feb 07, 2018), EU (Jun 21, 2018) 

Total Revenue: $13.42B 

Indications Approved: HIV Infection 

• Biktarvy is an antiviral regimen that combines bictegravir (an HIV-1 integrase strand transfer inhibitor), emtricitabine, and tenofovir alafenamide to treat HIV infection 

• Together, these three agents work synergistically to block the HIV integrase binding site, preventing strand transfer and halting viral integration into the host genome, an essential step in halting viral replication. In 2024, Biktarvy continued its strong performance, with global sales increasing 13.24% over 2023, propelled by sustained worldwide demand  

• 2024 marked an important regulatory milestone: the US FDA approved an updated label for Biktarvy that includes additional data demonstrating its safety and efficacy in pregnant individuals with HIV-1 who have suppressed viral loads, further strengthening its clinical profile and expanding its relevance in real-world care 

5. Dupixent 

Proprietary Name: Dupixent 

Non-Proprietary Name: Dupilumab 

Company: Sanofi & Regeneron Pharmaceuticals 

First Approved: US (Mar 28, 2017), EU (Sep 26, 2017) 

Total Revenue: $14.14B 

Indications Approved: Atopic Dermatitis, Asthma, Chronic Rhinosinusitis with Nasal Polyposis, Eosinophilic Esophagitis, Prurigo Nodularis, Chronic Obstructive Pulmonary Disease 

• Dupixent is an interleukin-4 receptor alpha antagonist delivered via subcutaneous injection. Available as a convenient single-dose prefilled pen or syringe, this monoclonal antibody is approved for multiple inflammatory conditions 

• By blocking IL-4 and IL-13 signaling; two key pathways that drive type 2 inflammation, Dupixent helps reduce symptoms and improve long-term disease control. The therapy continued its strong growth trajectory in 2024, with revenue rising 22.1%, supported by robust global demand  

• In Sep’24, Sanofi and Regeneron’s Dupixent received approval from both the US FDA and China’s NMPA for the treatment of COPD, expanding its reach into a new and highly impactful respiratory indication 

4. Mounjaro/Zepbound  

Proprietary Name: Mounjaro/Zepbound  

Non-Proprietary Name: Tirzepatide 

Company: Eli Lilly  

First Approved: US (May 13, 2022), EU (Sep 15, 2022) 

Total Revenue: $16.46B 

Indications Approved: Type 2 diabetes 

• Mounjaro is a once-weekly injectable therapy that targets both GIP and GLP-1 receptors to improve glycemic control in adults with type 2 diabetes. Tirzepatide, is also marketed as Zepbound for chronic weight management and, more recently, obstructive sleep apnea  

• Tirzepatide works by enhancing insulin secretion, reducing appetite, and slowing gastric emptying, mechanisms that support better glucose regulation and deliver substantial, clinically meaningful weight loss. The therapy’s momentum continued to build in 2024, with global sales surging more than 208.81%, fuelled by expanding obesity-related indications and strong demand across the US and Europe  

• In mid Dec’24, the US FDA approved Zepbound as the first-ever medication for obstructive sleep apnea, marking a major therapeutic milestone and expanding its reach beyond metabolic disease. 

3. Eliquis 

Proprietary Name: Eliquis 

Non-Proprietary Name: Apixaban 

Company: BMS, Pfizer 

First Approved: US (Dec 28, 2012), EU (May 18, 2011) 

Total Revenue: $20.69B 

Indications Approved: Prevention of Thromboembolism in Atrial Fibrillation, Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery, Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery 

• Eliquis is an oral factor Xa inhibitor prescribed to help prevent stroke and blood clots in patients with atrial fibrillation 

• By directly blocking factor Xa (FXa), the key enzyme that converts prothrombin to thrombin, Eliquis helps interrupt the clotting cascade and reduce the risk of dangerous thrombotic events. In 2024, global sales of Eliquis grew by 9.18% compared with 2023, driven by sustained demand across major markets  

• In 2024, the EMA’s CHMP adopted an extension of Eliquis’s indication to include the treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in children 

2. Ozempic/Wegovy/Rybelsus 

Proprietary Name: Ozempic/Wegovy/Rybelsus 

Non-Proprietary Name: Semaglutide 

Company: Novo Nordisk 

First Approved: Ozempic [US (Dec 05, 2017), EU (Feb 8, 2018)], Wegovy [US (Jun 4, 2021), EU (Jan 6, 2022)], Rybelsus [US (Sep 20, 2019), EU (Apr 3, 2020)] 

Total Revenue: $28.18B 

Indications Approved: Type 2 Diabetes, Obesity 

• Novo Nordisk’s semaglutide is marketed under three major brands, Ozempic and Rybelsus for type 2 diabetes, and Wegovy for obesity and weight management. 

• Semaglutide boosts incretin activity by activating GLP-1 receptors, prompting glucose-dependent insulin secretion, suppressing glucagon release, and lowering hepatic glucose production. Demand for semaglutide therapies remained exceptionally strong in 2024, with combined global sales across all brands rising 30.58% compared with 2023   

• Adding to momentum, in Dec’24, the European Medicines Agency (EMA) approved a label expansion for Ozempic to include a kidney disease-related indication 

1. Keytruda 

Proprietary Name: Keytruda 

Non-Proprietary Name: Pembrolizumab 

Company: Merck & Co. 

First Approved: US (Sep 04, 2014), EU (Jul 17, 2015) 

Total Revenue: $29.48B 

Indications Approved:  Melanoma, Non-Small Cell Lung Cancer, Malignant Pleural Mesothelioma, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Urothelial Carcinoma, Microsatellite Instability-High or Mismatch Repair Deficient Solid Tumors, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Cervical Cancer, Hepatocellular Carcinoma, Biliary Tract Cancer, Merkel Cell Carcinoma, Renal Cell Carcinoma, Endometrial Carcinoma, Tumor Mutational Burden-High Cancer, Cutaneous Squamous Cell Carcinoma, Triple-Negative Breast Cancer   

• Merck’s Keytruda, a PD-1–blocking antibody, is approved for multiple cancer indications including melanoma and non-small cell lung cancer 

• By inhibiting the PD-1/PD-L1 pathway, Keytruda helps reactivate T-lymphocytes, enabling the immune system to better recognize and attack tumor cells. In 2024, Keytruda’s global sales grew by 17.87% compared with 2023, fuelled by new indications and strong, sustained demand across established markets  

• In Nov’24, Merck reported positive data from a P-III study evaluating subcutaneous Keytruda (pembrolizumab) with berahyaluronidase alfa for patients with metastatic NSCLC, marking another step toward expanding treatment options and improving patient convenience  

Sources:         

• Annual reports       

• SEC Filings       

• Press releases       

• Company websites       

Currency Conversion: Oanda (£1 – $1.25, €1 – $1.04, kr.1 – 0.13, CHF 1 – 1.1, ₩1– 0.00068,  

HUF1 – 0.00253, ZAR1 – 0.0533, ¥1 – 0.13698; Dec 31, 2024)       

  

Related Post: Top 20 Prescription Drugs of 2025